U.S., June 19 -- ClinicalTrials.gov registry received information related to the study (NCT07657611) titled 'Inhaled mRNA Immunotherapy for Patients With Advanced Lung Cancer or Pulmonary Metastatic Solid Tumors' on June 14.
Brief Summary: This is an open-label phase I master platform study to evaluate the safety, tolerability and preliminary anti-tumor efficacy of multiple inhaled in-vivo mRNA immunotherapies in adult patients with advanced solid tumors. Subjects will receive inhalation mRNA formulations at ascending dose levels following a 3+3 dose-escalation design to determine maximum tolerated dose and recommended phase II dose.
Study Start Date: June 10
Study Type: INTERVENTIONAL
Condition:
Neoplasms
Solid Tumors
Neoplasm Metasta...